Cargando…
Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations
Currently available long-acting inhaled bronchodilators (tiotropium, salmeterol, formoterol) have demonstrated beneficial effects on exacerbations in placebo-controlled trials. However, there have been no direct comparisons of these drugs with exacerbations as the primary outcome and consequently CO...
Autores principales: | Beeh, Kai-Michael, Hederer, Bettina, Glaab, Thomas, Müller, Achim, Moelken, Maureen Rutten-van, Kesten, Steven, Vogelmeier, Claus |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672797/ https://www.ncbi.nlm.nih.gov/pubmed/19436693 |
Ejemplares similares
-
Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®)
por: Vogelmeier, Claus F., et al.
Publicado: (2015) -
Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
por: Hodder, Richard, et al.
Publicado: (2007) -
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017) -
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial
por: Beeh, Kai M, et al.
Publicado: (2013) -
The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD
por: Herth, Felix, et al.
Publicado: (2020)